Skip to main content
SpringerLink
Log in

Metabolic Syndrome and Nutritional Interventions

  • Chapter
  • First Online:
Functional Food and Human Health

  • 1594 Accesses

Abstract

Metabolic syndrome is a cluster of pathophysiological conditions that are associated with many other diseases including dyslipidaemia, cardiovascular diseases, insulin resistance and type 2 diabetes. Obesity is one of the many factors implicated in the progression of metabolic syndrome. Although some genetic components have been shown to be responsible for obesity, recent increase in the rate of obesity globally is mainly associated with the altered life-style (mostly sedentary) and food habit which includes consuming many and frequent meals during the day and energy-rich Westernized diet which are usually deficient of fibres and supply excessive calorie in shorter duration. Therefore, the weight loss by hypocaloric diet and life-style modifications are recommended to manage obesity and associated complications that come under metabolic syndrome. Recent focus on the functional food-derived nutrient components including polyphenols such as alkaloids, flavonoids, terpenes, saponins, etc. has advocated nutritional intervention in patients as a preventive and therapeutic approach for metabolic syndrome and life-style-associated diseases. In the present chapter, recent insight in the field of nutraceuticals and metabolic syndrome has been discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grundy SM et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227

    Article  PubMed  Google Scholar 

  2. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595

    Article  CAS  PubMed  Google Scholar 

  3. Evaluation and Treatment of High Blood Cholesterol in Adults Expert Panel on Detection (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19):2486–2497

    Article  Google Scholar 

  4. Luque CA, Rey JA (2002) The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 440(2–3):119–128

    Article  CAS  PubMed  Google Scholar 

  5. Xiao D et al (2013) Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs. Biochem Pharmacol 85(3):439–447

    Article  CAS  PubMed  Google Scholar 

  6. Poolsup N, Suksomboon N, Setwiwattanakul W (2012) Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. ISRN Endocrinol 2012:798146

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Van Gaal LF et al (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365(9468):1389–1397

    Article  PubMed  CAS  Google Scholar 

  8. Yki-Järvinen H (2004) Thiazolidinediones. N Engl J Med 351(11):1106–1118

    Article  PubMed  Google Scholar 

  9. Giorda C et al (1995) Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 44(5):673–676

    Article  CAS  PubMed  Google Scholar 

  10. Carpentier A et al (2002) Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 277(32):28795–28802

    Article  CAS  PubMed  Google Scholar 

  11. Knop FK, Bronden A, Vilsboll T (2017) Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother 18:555

    Article  CAS  PubMed  Google Scholar 

  12. Barnett A (2006) DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60(11):1454–1470

    Article  CAS  PubMed  Google Scholar 

  13. Mangaloglu L et al (2002) Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism 51(4):409–418

    Article  CAS  PubMed  Google Scholar 

  14. Bass A, Hinderliter AL, Lee CR (2009) The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. Ann Pharmacother 43(12):2021–2030

    Article  CAS  PubMed  Google Scholar 

  15. Buchwald H et al (2009) Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122(3):248–256 e5

    Article  PubMed  Google Scholar 

  16. Sjostrom CD et al (1999) Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 7(5):477–484

    Article  CAS  PubMed  Google Scholar 

  17. Flum DR, Dellinger EP (2004) Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg 199(4):543–551

    Article  PubMed  Google Scholar 

  18. Sowemimo OA et al (2007) Natural history of morbid obesity without surgical intervention. Surg Obes Relat Dis 3(1):73–77

    Article  PubMed  Google Scholar 

  19. Williams S, Cunningham E, Pories WJ (2012) Surgical treatment of metabolic syndrome. Med Princ Pract 21(4):301–309

    Article  PubMed  Google Scholar 

  20. Keidar A (2011) Bariatric surgery for type 2 diabetes reversal: the risks. Diabetes Care 34(Suppl 2):S361–S266

    Article  PubMed  PubMed Central  Google Scholar 

  21. Mason EE, Ito C (1967) Gastric bypass in obesity. Surg Clin North Am 47(6):1345–1351

    Article  CAS  PubMed  Google Scholar 

  22. Marceau P et al (1998) Biliopancreatic diversion with duodenal switch. World J Surg 22(9):947–954

    Article  CAS  PubMed  Google Scholar 

  23. Cătoi AF et al (2016) Effects of sleeve gastrectomy on insulin resistance. Clujul Med 89(2):267–272

    Article  PubMed  PubMed Central  Google Scholar 

  24. Muzio F et al (2005) Long-term effects of low-calorie diet on the metabolic syndrome in obese nondiabetic patients. Diabetes Care 28(6):1485–1486

    Article  PubMed  Google Scholar 

  25. Wadden TA et al (2005) Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353(20):2111–2120

    Article  CAS  PubMed  Google Scholar 

  26. Berthoud HR (2002) Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26(4):393–428

    Article  PubMed  Google Scholar 

  27. Bray GA (2008) Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab 93(11 Suppl 1):S81–S88

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Knowler WC et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403

    Article  CAS  PubMed  Google Scholar 

  29. Orchard TJ et al (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Ann Intern Med 142(8):611–619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fabricatore AN (2007) Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference? J Am Diet Assoc 107(1):92–99

    Article  PubMed  Google Scholar 

  31. Ferster CB, Nurnberger JI, Levitt EB (1996) The control of eating. 1962. Obes Res 4(4):401–410

    CAS  PubMed  Google Scholar 

  32. Gruber KJ, Haldeman LA (2009) Using the family to combat childhood and adult obesity. Prev Chronic Dis 6(3):A106

    PubMed  PubMed Central  Google Scholar 

  33. Grave RD et al (2010) Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes Metab Syndr Obes 3:373–385

    Article  PubMed Central  Google Scholar 

  34. D'Zurilla TJ, Goldfried MR (1971) Problem solving and behavior modification. J Abnorm Psychol 78(1):107–126

    Article  CAS  PubMed  Google Scholar 

  35. Shahidi F, Ambigaipalan P (2015) Phenolics and polyphenolics in foods, beverages and spices: antioxidant activity and health effects – a review. J Func Foods 18(Part B):820–897

    Article  CAS  Google Scholar 

  36. Messina M, Messina V (1996) Nutritional implications of dietary phytochemicals. Adv Exp Med Biol 401:207–212

    Article  CAS  PubMed  Google Scholar 

  37. Hegsted DM (1994) A look back at lessons learned and not learned. J Nutr 124(9 Suppl):1867S–1870S

    Article  CAS  PubMed  Google Scholar 

  38. Sauer S, Plauth A (2017) Health-beneficial nutraceuticals—myth or reality? Appl Microbiol Biotechnol 101(3):951–961

    Article  CAS  PubMed  Google Scholar 

  39. Agrawal DK, Mishra PK (2010) Curcumin and its analogues: potential anticancer agents. Med Res Rev 30(5):818–860

    CAS  PubMed  Google Scholar 

  40. Leu TH, Maa MC (2002) The molecular mechanisms for the antitumorigenic effect of curcumin. Curr Med Chem Anticancer Agents 2(3):357–370

    Article  CAS  PubMed  Google Scholar 

  41. Dai J, Mumper RJ (2010) Plant Phenolics: extraction, analysis and their antioxidant and anticancer properties. Molecules 15(10):7313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Park EJ, Pezzuto JM (2015) The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta 1852(6):1071–1113

    Article  CAS  PubMed  Google Scholar 

  43. Iwai K et al (2006) α-Glucosidase inhibitory and Antihyperglycemic effects of polyphenols in the fruit of Viburnum dilatatum Thunb. J Agric Food Chem 54(13):4588–4592

    Article  CAS  PubMed  Google Scholar 

  44. Iwai K (2008) Antidiabetic and antioxidant effects of polyphenols in brown alga Ecklonia stolonifera in genetically diabetic KK-A(y) mice. Plant Foods Hum Nutr 63(4):163–169

    Article  CAS  PubMed  Google Scholar 

  45. Cabrera C, Artacho R, Gimenez R (2006) Beneficial effects of green tea--a review. J Am Coll Nutr 25(2):79–99

    Article  CAS  PubMed  Google Scholar 

  46. Kobayashi Y et al (2000) Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. J Agric Food Chem 48(11):5618–5623

    Article  CAS  PubMed  Google Scholar 

  47. Johnston K et al (2005) Dietary polyphenols decrease glucose uptake by human intestinal Caco-2 cells. FEBS Lett 579(7):1653–1657

    Article  CAS  PubMed  Google Scholar 

  48. Rivera L et al (2008) Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 16(9):2081–2087

    Article  CAS  Google Scholar 

  49. Bose M et al (2008) The major green tea polyphenol, (−)-Epigallocatechin-3-Gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat–fed mice. J Nutr 138(9):1677–1683

    Article  CAS  PubMed  Google Scholar 

  50. Egert S et al (2010) Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 140(2):278–284

    Article  CAS  PubMed  Google Scholar 

  51. Mulvihill EE et al (2009) Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes 58(10):2198–2210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Yokozawa T, Kim HJ, Cho EJ (2008) Gravinol ameliorates high-fructose-induced metabolic syndrome through regulation of lipid metabolism and proinflammatory state in rats. J Agric Food Chem 56(13):5026–5032

    Article  CAS  PubMed  Google Scholar 

  53. Shabrova EV et al (2011) Insights into the molecular mechanisms of the anti-atherogenic actions of flavonoids in normal and obese mice. PLoS One 6(10):e24634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Mulvihill EE et al (2010) Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat–fed low-density lipoprotein receptor–null mice. Arterioscler Thromb Vasc Biol 30(4):742

    Article  CAS  PubMed  Google Scholar 

  55. Huang HC, Lin JK (2012) Pu-erh tea, green tea, and black tea suppresses hyperlipidemia, hyperleptinemia and fatty acid synthase through activating AMPK in rats fed a high-fructose diet. Food Funct 3(2):170–177

    Article  CAS  PubMed  Google Scholar 

  56. Gordon MH (2012) Significance of dietary antioxidants for health. Int J Mol Sci 13(1):173–179

    Article  CAS  PubMed  Google Scholar 

  57. Erdman JW et al (2007) Flavonoids and heart health: proceedings of the ILSI North America flavonoids workshop, May 31–June 1, 2005, Washington, DC. J Nutr 137(3):718S–737S

    Article  CAS  PubMed  Google Scholar 

  58. Kasubuchi M et al (2015) Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients 7(4):2839–2849

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ley RE et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444(7122):1022–1023

    Article  CAS  PubMed  Google Scholar 

  60. Yoo J, Kim S (2016) Probiotics and prebiotics: present status and future perspectives on metabolic disorders. Nutrients 8(3):173

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Muller M, Kersten S (2003) Nutrigenomics: goals and strategies. Nat Rev Genet 4(4):315–322

    Article  PubMed  CAS  Google Scholar 

  62. Fenech M et al (2011) Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice. J Nutrigenet Nutrigenomics 4(2):69–89

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Gaedigk A et al (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48(5):943–950

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5(1):6–13

    Article  CAS  PubMed  Google Scholar 

  65. Gonzalez FJ et al (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331(6155):442–446

    Article  CAS  PubMed  Google Scholar 

  66. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336(8714):529–532

    Article  CAS  PubMed  Google Scholar 

  67. Kalow W (1986) Ethnic differences in reactions to drugs and xenobiotics. Caffeine and other drugs. Prog Clin Biol Res 214:331–341

    CAS  PubMed  Google Scholar 

  68. Simopoulos AP (2010) Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Exp Biol Med (Maywood) 235(7):785–795

    Article  CAS  Google Scholar 

  69. Sameer AS et al (2011) ACE I/D polymorphism in hypertensive patients of Kashmiri population. Cardiol Res 1(1):1–7

    Google Scholar 

  70. Rahimi Z (2012) ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy. J Nephropathol 1(3):143–151

    Article  PubMed  PubMed Central  Google Scholar 

  71. Perticone F et al (1998) Angiotensin-converting enzyme gene polymorphism is associated with endothelium-dependent vasodilation in never treated hypertensive patients. Hypertension 31(4):900

    Article  CAS  PubMed  Google Scholar 

  72. Tiret L et al (1993) Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet 341(8851):991–992

    Article  CAS  PubMed  Google Scholar 

  73. Ruiz J et al (1994) Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 91(9):3662–3665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Navis G et al (1999) Angiotensin-converting enzyme gene I/D polymorphism and renal disease. J Mol Med 77(11):781–791

    Article  CAS  PubMed  Google Scholar 

  75. Rahimi Z et al (2011) The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria. Mol Biol Rep 38(3):2117–2123

    Article  CAS  PubMed  Google Scholar 

  76. Engeli S, Negrel R, Sharma AM (2000) Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35(6):1270–1277

    Article  CAS  PubMed  Google Scholar 

  77. Lee YJ, Tsai JC (2002) ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Diabetes Care 25(6):1002–1008

    Article  CAS  PubMed  Google Scholar 

  78. Connor WE, Connor SL (1997) Should a low-fat, high-carbohydrate diet be recommended for everyone? The case for a low-fat, high-carbohydrate diet. N Engl J Med 337(8):562–563; discussion 566-7

    Article  CAS  PubMed  Google Scholar 

  79. Heird WC, Lapillonne A (2005) The role of essential fatty acids in development. Annu Rev Nutr 25:549–571

    Article  CAS  PubMed  Google Scholar 

  80. Cho HP, Nakamura M, Clarke SD (1999) Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. J Biol Chem 274(52):37335–37339

    Article  CAS  PubMed  Google Scholar 

  81. Marquardt A et al (2000) cDNA cloning, genomic structure, and chromosomal localization of three members of the human fatty acid desaturase family. Genomics 66(2):175–183

    Article  CAS  PubMed  Google Scholar 

  82. Schaeffer L et al (2006) Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 15(11):1745–1756

    Article  CAS  PubMed  Google Scholar 

  83. Pitsavos C et al (2006) Diet, exercise and the metabolic syndrome. Rev Diabet Stud 3(3):118–126

    Article  PubMed  PubMed Central  Google Scholar 

  84. Anderson CA, Miller ER 3rd (2006) Dietary recommendations for obese patients with chronic kidney disease. Adv Chronic Kidney Dis 13(4):394–402

    Article  PubMed  Google Scholar 

  85. Trichopoulou A, Lagiou P (1997) Healthy traditional Mediterranean diet: an expression of culture, history, and lifestyle. Nutr Rev 55(11 Pt 1):383–389

    CAS  PubMed  Google Scholar 

  86. Abramson JL, Vaccarino V (2002) Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med 162(11):1286–1292

    Article  PubMed  Google Scholar 

  87. MacAuley D et al (1996) Physical activity, physical fitness, blood pressure, and fibrinogen in the Northern Ireland health and activity survey. J Epidemiol Community Health 50(3):258–263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Yamaoka K, Tango T (2012) Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Med 10(1):138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106(25):3143–3421

    Article  Google Scholar 

  90. Mozaffarian D, Ludwig DS (2010) Dietary guidelines in the 21st century–a time for food. JAMA 304(6):681–682

    Article  CAS  PubMed  Google Scholar 

  91. Myers J (2003) Exercise and cardiovascular health. Circulation 107(1):e2, 2e

    Article  Google Scholar 

  92. Paffenbarger RSJ et al (1993) The Association of Changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 328(8):538–545

    Article  PubMed  Google Scholar 

  93. Mann S, Beedie C, Jimenez A (2014) Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports med 44(2):211–221

    Article  PubMed  Google Scholar 

  94. Srinath Reddy K, Katan MB (2004) Diet, nutrition and the prevention of hypertension and cardiovascular diseases. Public Health Nutr 7(1A):167–186

    CAS  PubMed  Google Scholar 

  95. MacCracken J, Hoel D (1997) From ants to analogues. Puzzles and promises in diabetes management. Postgrad Med 101(4):138–140 143–5, 149–50

    Article  CAS  PubMed  Google Scholar 

  96. Tipton CM (2008) Susruta of India, an unrecognized contributor to the history of exercise physiology. J Appl Physiol (1985) 104(6):1553–1556

    Article  Google Scholar 

  97. Westley RL, May FE (2013) A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol 2013:632461

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Riccardi G, Rivellese AA (2000) Dietary treatment of the metabolic syndrome – the optimal diet. Br J Nutr 83(Suppl 1):S143–S148

    CAS  PubMed  Google Scholar 

  99. Wirth A (1995) Non-pharmacological therapy of metabolic syndrome. Herz 20(1):56–69

    CAS  PubMed  Google Scholar 

  100. Garg SK et al (2014) Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 16(2):97–110

    Article  CAS  PubMed  Google Scholar 

  101. Global Burden of Disease Cancer Collaboration (2015) The global burden of cancer 2013. JAMA Oncol 1(4):505–527

    Article  PubMed Central  Google Scholar 

  102. Renehan AG et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578

    Article  PubMed  Google Scholar 

  103. Vigneri P et al (2009) Diabetes and cancer. Endocr Relat Cancer 16(4):1103–1123

    Article  CAS  PubMed  Google Scholar 

  104. Shanmugam MK et al (2015) The multifaceted role of curcumin in cancer prevention and treatment. Molecules 20(2):2728–2769

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  105. Dalziel K, Segal L (2007) Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions. Health Promot Int 22(4):271–283

    Article  PubMed  Google Scholar 

  106. Hoffman R, Gerber M (2015) Food processing and the Mediterranean diet. Nutrients 7(9):7925–7964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgement

The Ramanujan Fellowship to UCSY from DST, Government of India, is acknowledged thankfully.

Author information

Authors and Affiliations

  1. Metabolic Disorders and Inflammatory Pathologies Laboratory, School of Life Sciences, Central University of Gujarat, Gandhinagar, Gujarat, India

    Bhawna Kumari & Akanksha Sharma

  2. School of Life Sciences, Central University of Gujarat, Gandhinagar, Gujarat, India

    Umesh C. S. Yadav

Authors
  1. Bhawna Kumari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akanksha Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Umesh C. S. Yadav
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Umesh C. S. Yadav .

Editor information

Editors and Affiliations

  1. Department of Biotechnology, Jaypee Institute of Information Technology, Noida, Uttar Pradesh, India

    Vibha Rani

  2. School of Life Sciences, Central University of Gujarat, Gandhinagar, Gujarat, India

    Umesh C. S. Yadav

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kumari, B., Sharma, A., Yadav, U.C.S. (2018). Metabolic Syndrome and Nutritional Interventions. In: Rani, V., Yadav, U. (eds) Functional Food and Human Health. Springer, Singapore. https://doi.org/10.1007/978-981-13-1123-9_13

Download citation

Publish with us

Policies and ethics

Search

Navigation